CVS Health (CVS) Shares Surge 5% on $13B Medicare Advantage Payment Increase

KEY TAKEAWAYS

• CMS approved 2027 Medicare Advantage payment guidelines with a net 2.48% average increase — representing more than $13 billion in additional industry funding
• Shares of CVS climbed up to 5.20% on Tuesday as investors welcomed the news for its Aetna insurance division
• The 2024 risk-adjustment model will remain in effect for 2027, with stricter guidelines on diagnoses from unlinked chart reviews
• Cantor Fitzgerald maintains an Overweight rating and $95 price target, highlighting Medicare Advantage margin improvement as a catalyst
• First-quarter 2026 earnings are scheduled for May 6, with analysts forecasting $2.23 EPS and $94.86 billion in revenue

CVS Health experienced a strong trading session on Tuesday following a Medicare Advantage policy announcement that lifted managed-care stocks across the board.

CVS Health Corporation, CVS

The Centers for Medicare & Medicaid Services released its final 2027 Medicare Advantage and Part D payment policies, outlining a net average payment increase of 2.48% — equivalent to over $13 billion in additional sector-wide funding for the 2027 calendar year.

For CVS, this development carries significant weight. The company maintains substantial Medicare Advantage exposure through Aetna, complementing its pharmacy benefit management and retail pharmacy businesses.

Investors responded favorably to the announcement. Shares of CVS rose as high as 5.20% during Tuesday’s session.

New Risk-Adjustment Standards Introduce Nuance

The CMS update included some additional details worth noting. The agency confirmed it will maintain the 2024 risk-adjustment model through 2027 and will disallow diagnoses from unlinked chart reviews in most risk-score determinations.

This represents a more stringent approach that may impact insurers relying heavily on coding-based reimbursement tactics. For CVS, with its broad operational footprint, market participants seemed to prioritize the overall funding boost over the risk-adjustment modifications.

CVS has also seen improvement in its Stars ratings profile. The percentage of bonus-eligible Stars scores plummeted from 85% in 2022 to just 21% in 2023 — a decline that significantly pressured Medicare Advantage profitability.

Cantor Fitzgerald, which reaffirmed its Overweight rating and $95 price target earlier this week, noted that while the Medicare Advantage segment hasn’t yet achieved 3% margins, the firm estimates that 2026 individual Medicare Advantage operations are now marginally profitable.

Prior to Tuesday’s rally, shares traded at $73.28, a price point that Cantor and other analysts consider below intrinsic value.

Wall Street Remains Optimistic Ahead of Earnings

Analyst sentiment toward CVS has remained predominantly positive. The stock holds a consensus Buy rating with an average price target of $92.79.

Recent analyst actions include Bernstein’s upgrade to Outperform with a $94 target in March, Piper Sandler maintaining Overweight while adjusting its target to $99, and Argus Research keeping a Buy rating at $90.

Leerink Partners also maintains an Outperform rating with a $98 price objective, influenced partly by the recent FTC consent decree involving Caremark and Zinc, which analysts viewed as reducing regulatory overhang.

On the operational front, CVS recently entered into an asset purchase agreement with GenieRx Holdings, designating GenieRx as the stalking horse bidder for Omnicare’s court-supervised divestiture process.

The company has also added John E. Gallina, former CFO of Elevance Health, to its board of directors and audit committee.

Looking ahead: CVS is set to release first-quarter 2026 results on May 6. Wall Street consensus calls for earnings per share of $2.23 on revenue of $94.86 billion.

The post CVS Health (CVS) Shares Surge 5% on $13B Medicare Advantage Payment Increase appeared first on Blockonomi.